Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Rhea-AI Summary
Glucotrack (Nasdaq:GCTK) received a USPTO Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.” The allowed claims expand protection of its fully implantable continuous blood glucose monitoring (CBGM) platform.
The filing adds to three CBGM patents issued in late 2025 and covers intravascular sensing leads, electronics assemblies, electrode configurations, and implantation methods. Glucotrack’s CBGM is designed as a long-term implantable system with no wearable component, targeting up to three years of continuous, blood-based glucose monitoring with real-time readings.
Positive
- USPTO Notice of Allowance expands protection of implantable CBGM platform
- Adds to three CBGM patents issued by USPTO in late 2025
- Claims cover intravascular sensing leads and electronics assembly architectures
- IP supports strategy to advance fully implantable system toward commercialization
- CBGM designed for up to three years of continuous blood glucose monitoring
- System has no wearable component, aiming to reduce patient burden
Negative
- None.
News Market Reaction – GCTK
In the Jul 8 session, GCTK gained 1.69%, reflecting a mild positive market reaction. Argus tracked a peak move of +29.4% during that session. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 2.0x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | technology showcase | Positive | +18.9% | Showcasing implantable CBGM technology and data at ADA 2026 sessions. |
| May 14 | earnings report | Positive | -3.0% | Q1 2026 results with IDE submission, debt reduction, and narrower net loss. |
| May 07 | IDE submission | Positive | +0.8% | FDA IDE submission to start U.S. clinical study of implantable CBGM system. |
| Apr 30 | clinical data | Positive | -7.3% | Peer‑reviewed ovine study showing long‑term accuracy and stability of CBGM tech. |
| Apr 21 | clinical data | Positive | -4.0% | Publication supporting long‑life sensor design for implantable CBGM platform. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent development headlines have more often been followed by negative share moves than by rallies.
Key Terms
uspto regulatory
notice of allowance regulatory
continuous blood glucose monitoring medical
intravascular medical
interstitial fluid medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient.” The allowed claims expand the intellectual property protecting the Company’s continuous blood glucose monitoring (CBGM) platform as it advances its multi-year, fully implantable CBGM system toward commercialization.
The filing adds to the three CBGM patents issued by the USPTO in late 2025 (US 12,453,494; US 12,458,257; and US 12,458,258), further protecting key technologies across the Company's sensor architecture.
The allowed claims cover implantable glucose monitoring systems that utilize an intravascular sensing lead coupled to an electronics assembly, including device architectures and methods designed to operate within the vasculature to support long-term glucose monitoring. The claims further encompass electrode configurations, lead-based sensing structures, and associated implantation methods for continuous glucose measurement.
“This allowed application strengthens the protection around key elements of our CBGM, including novel sensor architectures designed to support long-term intravascular glucose monitoring,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “Continuing to build our intellectual property is fundamental to our strategy as we advance the fully implantable system through clinical testing and toward commercialization.”
Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less burdensome glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of up to 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
| Contacts: | |
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
